All In Biotech

Drug Trial Radar · NCT03736369

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

A Multi-Center, Randomized, Double-Blind, Active-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease

Last checked: Nov 19, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 263 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

263

Actual

Start

Dec 13, 2018

Primary completion

Aug 7, 2019

Study completion Aug 7, 2019

Sponsor

Sponsor type
Industry
First posted
Nov 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.

Conditions

  • Erosive Esophagitis

Interventions

  • DWP14012 40mgDrug

    DWP14012 40mg, tablet, orally, once daily for up to 8 weeks

  • DWP14012 40mg placeboDrug

    DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks

  • Esomeprazole 40mgDrug

    Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks

  • Esomeprazole 40mg placeboDrug

    Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative healing rate of erosive esophagitis at 8week by endoscopyTime frame: at 8week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hanyang University Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.